By taking advantage of the selectivity of monoclonal antibodies, these platforms preferentially target tumor-associated antigens (TAAs) including HER2, TROP-2, HER3 and LIV-1, which avoids off-target toxicity and overcomes drug resistance. Here, SLC39A6 is linked to neoplasm.